GlassScriptPhysician profile
Garfield Ramdeen
NPI 1922191022
$1,874.52
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $478 · 2021: $306 · 2023: $26.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $438.25 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $283.22 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $194.20 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $173.32 | 2019-2020 | |
| Horizon Therapeutics Plc | $150.29 | 2019-2021 | |
| Akebia Therapeutics INC | $141.54 | 2019-2020 | |
| Baxter Healthcare | $133.55 | 2019 | |
| Vifor Pharma, INC. | $69.15 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $68.20 | 2019 | |
| Mallinckrodt Enterprises LLC | $34.10 | 2019 | |
| Shire North American Group INC | $32.61 | 2019 | |
| Glaxosmithkline, LLC. | $31.71 | 2021 | |
| Travere Therapeutics, INC. | $26.41 | 2023 | |
| Daiichi Sankyo INC. | $19.22 | 2019 | |
| Recordati_rare_diseases_inc. | $18.37 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $17.82 | 2020 | |
| Mallinckrodt Hospital Products INC. | $15.68 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.14 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garfield Ramdeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.